URGN

UroGen Pharma Ltd

28.61

Nov 04 • 2:59 PM ET -5.79 (-16.84%)

Healthcare Biotechnology USA Small NASD

Today, 8:36 AMUroGen Pharma Q3 2026 revenue $89.0M (+224% YoY) misses estimates as FDA accepts UGN-103 NDA with June 14, 2027 PDUFA date

Peers: CGON ENGN RLMD TARA JANX TLX AKTS EXEL PBYI ARTV

| Held by: IWM IWO IBB VTWO FESM SPDW VHT IWC IWN IZRL

Scroll to Statements

Index	RUT
Market Cap	1.40B
Enterprise Value	1.49B
Income	-97.64M
Sales	188.73M
Book/sh	-2.71
Cash/sh	2.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	291
IPO	May 04, 2017

P/E	-
Forward P/E	10.05
PEG	-
P/S	7.41
P/B	-
P/C	12.79
P/FCF	-
EV/EBITDA	-
EV/Sales	7.87
Quick Ratio	3.41
Current Ratio	3.80
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.99
EPS next Y	2.85
EPS next Q	0.44
EPS this Y	94.13%
EPS next Y	1621.37%
EPS next 5Y	-
EPS past 3/5Y	12.81% 11.57%
Sales past 3/5Y	19.49% 56.22%
EPS Y/Y TTM	39.90%
Sales Y/Y TTM	100.27%
EPS Q/Q	72.78%
Sales Q/Q	199.22%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	-128.38% -1.02%

Insider Own	15.09%
Insider Trans	-1.34%
Inst Own	80.55%
Inst Trans	0.17%
ROA	-42.33%
ROE	-
ROIC	-158.40%
Gross Margin	90.85%
Oper. Margin	-35.32%
Profit Margin	-51.73%
SMA20	-17.99%
SMA50	-27.76%
SMA200	-9.19%
Trades

Shs Outstand	48.87M
Shs Float	41.50M
Short Float	13.51%
Short Ratio	5.79
Short Interest	5.61M
52W High	50.81 -43.70%
52W Low	16.50 73.38%
Volatility	4.61% 5.46%
ATR (14)	2.13
RSI (14)	23.31
Beta	1.64
Rel Volume	2.74
Avg Volume	968.67K
Volume	2,262,473

Perf Week	-15.24%
Perf Month	-30.95%
Perf Quarter	-37.26%
Perf Half Y	8.98%
Perf YTD	22.15%
Perf Year	44.41%
Perf 3Y	147.26%
Perf 5Y	50.25%
Perf 10Y	-
Recom	1.00
Target Price	61.71
Prev Close	34.40
Price	28.61
Change %	-16.84%

Consensus

Strong Buy

Avg. Price Target

$61.71

Implied Upside

+115.7%

Analysts12incl. previous ratings

Rating Distribution9 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 11, 2026	Resumed	LLadenburg Thalmann	Buy	$43	+50.3%
Apr 10, 2026	Initiated	JJefferies	Buy	$40	+39.8%
Aug 19, 2025	Initiated	PPiper Sandler	Overweight	$36	+25.8%
Jun 16, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$50	+74.8%
May 22, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Apr 16, 2025	Initiated	BScotiabank	Sector Outperform	$23	-19.6%
Feb 19, 2025	Resumed	LLadenburg Thalmann	Buy	$31	+8.4%
Aug 22, 2024	Initiated	GGuggenheim	Buy	$40	+39.8%
Feb 08, 2023	Downgrade	JJefferies	Buy → Hold	$35 → $10	-65.0%
Apr 27, 2022	Initiated	BBerenberg	Buy	$20	-30.1%
Apr 16, 2020	Reiterated	HH.C. Wainwright	Buy	$53 → $57	+99.2%
Apr 13, 2020	Reiterated	HH.C. Wainwright	Buy	$75 → $53	+85.3%
Jan 09, 2020	Initiated	NNational Securities	Neutral	$37	+29.3%
May 30, 2019	Initiated	JJP Morgan	Neutral
May 29, 2019	Initiated	GGoldman	Neutral
Jan 29, 2019	Initiated	HH.C. Wainwright	Buy	$82	+186.6%
Nov 08, 2018	Resumed	JJefferies	Buy
Apr 04, 2018	Upgrade	RRaymond James	Mkt Perform → Outperform
Jan 02, 2018	Initiated	LLadenburg Thalmann	Buy	$50	+74.8%
Nov 15, 2017	Reiterated	OOppenheimer	Outperform	$32 → $51	+78.3%

Today 08:00AM	UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights (GlobeNewswire) -16.84%
Nov-03-26 08:00AM	UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
Nov-02-26 08:00AM	UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +5.01%
Oct-28-26 08:00AM	UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer (GlobeNewswire)
Oct-27-26 08:42PM	UroGen's Zysturi Ramp Faces A Summer Test As Wall Street Pencils In A Profit (Earnings Whispers)
06:00PM	Loading…
06:00PM	UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 (GlobeNewswire)
Oct-19-26 08:00AM	UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC (GlobeNewswire)
Sep-09-26 10:44AM	Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress (Barrons.com)
Sep-04-26 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-26 07:00AM	UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline (GlobeNewswire) -6.94%
Aug-17-26 08:00AM	UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC (GlobeNewswire)
Aug-05-26 05:07PM	UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cysview Revenue Surges 73% as Net ... (GuruFocus.com) +16.31%
08:00AM	UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights (GlobeNewswire)
Jul-29-26 08:00AM	UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 (GlobeNewswire)
11:07PM	Loading…
Jul-21-26 11:07PM	Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? (Stocktwits) +6.47%
Jul-15-26 08:00AM	UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI and UGN-103 (GlobeNewswire)
Jul-08-26 08:00AM	UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jun-05-26 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-26 08:00AM	UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO (mitomycin) for pyelocalyceal solution (GlobeNewswire)
Jun-01-26 04:10PM	UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-15-26 08:00AM	UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC (GlobeNewswire)
May-13-26 08:00AM	ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial (GlobeNewswire)
May-07-26 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-26 08:00AM	UroGen Reports ZUSDURI Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights (GlobeNewswire) +10.16%
Apr-29-26 08:00AM	UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (GlobeNewswire) +5.93%
Mar-30-26 08:00AM	Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI (GlobeNewswire)
Mar-13-26 08:00AM	UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence (GlobeNewswire)
Mar-06-26 04:10PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:02PM	Loading…
Mar-02-26 04:02PM	UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com) -12.35%
12:15PM	Urogen Pharma Q4 Earnings Call Highlights (MarketBeat)
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:00AM	UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
07:55AM	UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors (GlobeNewswire)
Feb-27-26 08:30AM	ZUSDURI Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC (GlobeNewswire)
Feb-24-26 04:05PM	UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-23-26 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 (GlobeNewswire)
Feb-15-26 08:06PM	UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target (MarketBeat)
Feb-04-26 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-06-26 08:37AM	UroGen Pharma says permanent J Code for ZUSDURI now in effect (TipRanks)
Jan-05-26 08:00AM	Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy (GlobeNewswire)
Dec-05-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.35%
Nov-25-25 08:00AM	UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-16-25 10:14PM	UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs (Insider Monkey)
Nov-06-25 04:20PM	UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +21.91%
09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI Launch Gains Momentum (GlobeNewswire)
07:58AM	UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial (GlobeNewswire)
Nov-04-25 08:00AM	UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 (GlobeNewswire)
07:15AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-29-25 10:00AM	Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 08:00AM	Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 (GlobeNewswire) +9.91%
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks)
Oct-02-25 08:00AM	ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Sep-08-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.45%
Aug-21-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 03:25AM	UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... (GuruFocus.com)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.10%
08:00AM	UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 08:06AM	UroGens Zusduri benefit maintained in NMIBC Phase III study (Clinical Trials Arena)
Aug-05-25 08:00AM	UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-30-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss (Zacks)
Jul-29-25 08:00AM	UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 (GlobeNewswire)
01:31AM	UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology (Insider Monkey)
Jul-28-25 08:00AM	UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology (GlobeNewswire)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
08:00AM	UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-08-25 11:48AM	UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer (Clinical Trials Arena)
Jul-07-25 08:00AM	UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-06-25 04:01AM	UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer (Insider Monkey)
Jun-17-25 01:32PM	H.C. Wainwright Sees Billion Dollar Potential in UroGen's New Therapy (Insider Monkey) -7.67%
Jun-13-25 12:40PM	FDA approves UroGens Zusduri for non-muscle invasive bladder cancer (TipRanks) +8.57%
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:45AM	UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN (PR Newswire)
Jun-12-25 01:28PM	U.S. FDA Approves UroGens ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) +51.78%
Jun-06-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +43.39%
Jun-02-25 11:00AM	UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer (Business Wire) +14.15%
10:00AM	UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
May-29-25 01:45PM	UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman (PR Newswire)
May-27-25 04:00PM	UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Business Wire) -6.21%
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 12:17PM	UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) -44.69%
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.40%
May-13-25 03:05AM	UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... (GuruFocus.com) -8.98%
May-12-25 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.32%
08:00AM	UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-07-25 10:32AM	Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month (Seeking Alpha)
10:22AM	UroGen's bladder cancer treatment to be reviewed by FDA advisory committee (Seeking Alpha)
08:57AM	UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
May-01-25 04:00PM	UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (Business Wire)
Apr-29-25 05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-27-25 04:00PM	OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment (Business Wire)
01:00PM	New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC (Business Wire)
12:30PM	New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC (Business Wire)
Apr-26-25 06:30PM	UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
10:00AM	UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-14-25 08:00AM	UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Degnan Chris	Chief Financial Officer	Oct 08 '26	Sale	36.69	2,202	80,791	4,561	Oct 09 12:57 PM
Christopher Degnan	Officer	Oct 08 '26	Proposed Sale	40.70	2,202	89,621		Oct 09 06:23 AM
Schoenberg Mark	Chief Medical Officer	Sep 08 '26	Sale	42.92	871	37,383	59,882	Sep 09 02:37 PM
Smith Jason Drew	General Counsel	Sep 08 '26	Sale	42.54	1,519	64,618	53,141	Sep 09 02:35 PM
Mark Schoenberg	Officer	Sep 08 '26	Proposed Sale	44.09	871	38,402		Sep 09 07:34 AM
Jason Smith	Officer	Sep 08 '26	Proposed Sale	44.09	1,519	66,973		Sep 09 07:34 AM
Schoenberg Mark	Chief Medical Officer	Aug 20 '26	Sale	47.05	60,677	2,854,853	59,086	Aug 24 05:03 PM
Schoenberg Mark	Officer	Aug 20 '26	Proposed Sale	47.67	60,677	2,892,242		Aug 20 01:24 PM
Schoenberg Mark	Chief Medical Officer	Jul 09 '26	Sale	40.00	10,000	400,000	119,763	Jul 10 02:17 PM
Schoenberg Mark	Officer	Jul 09 '26	Proposed Sale	40.00	10,000	400,008		Jul 09 04:19 PM
Schoenberg Mark	Chief Medical Officer	Jun 22 '26	Sale	35.01	10,000	350,100	129,763	Jun 24 10:22 AM
Schoenberg Mark	Officer	Jun 22 '26	Proposed Sale	35.01	10,000	350,143		Jun 22 03:53 PM
Schoenberg Mark	Chief Medical Officer	Jun 08 '26	Sale	27.30	5,222	142,561	139,763	Jun 09 01:59 PM
Schoenberg Mark	Officer	Jun 08 '26	Proposed Sale	26.85	5,222	140,211		Jun 09 07:50 AM
Schoenberg Mark	Chief Medical Officer	May 08 '26	Sale	30.00	10,000	300,000	134,985	May 11 03:54 PM
Schoenberg Mark	Officer	May 08 '26	Proposed Sale	30.00	10,000	300,048		May 08 12:55 PM
Smith Jason Drew	General Counsel	Feb 03 '26	Sale	19.69	7,479	147,262	51,326	Feb 11 02:54 PM
Schoenberg Mark	Chief Medical Officer	Feb 03 '26	Sale	19.69	7,373	145,174	144,985	Feb 04 07:37 PM
Schoenberg Mark	Officer	Feb 02 '26	Proposed Sale	19.61	13,333	261,460		Feb 03 07:53 AM
Schoenberg Mark	Chief Medical Officer	Nov 19 '25	Sale	25.00	10,000	250,000	139,025	Nov 20 01:42 PM
Schoenberg Mark	Officer	Nov 19 '25	Proposed Sale	25.00	10,000	250,005		Nov 19 03:19 PM

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

PresidentMs. Elizabeth A. Barrett

General CounselMr. Jason Drew Smith J.D.

Chief Medical OfficerDr. Mark P. Schoenberg M.D.

Chief Financial OfficerMr. Christopher Degnan CPA

Senior Director of Investor RelationsMr. Vincent I. Perrone

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your Finviz experience